Acute Ischemic Stroke Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Acute Ischemic Stroke Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 35+ key pharma and biotech companies are working on 35+ pipeline drugs in the Acute Ischemic Stroke therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Acute Ischemic Stroke Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Ischemic Stroke Market. 

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Acute Ischemic Stroke Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Acute Ischemic Stroke and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Acute Ischemic Stroke Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Acute Ischemic Stroke Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Acute Ischemic Stroke Therapeutic Segment @

Acute Ischemic Stroke Therapeutics Landscape

There are approx. 35+ key Acute Ischemic Stroke companies which are developing Acute Ischemic Stroke therapies. Currently, GNT Pharma is leading the therapeutics market with its Acute Ischemic Stroke drug candidates in the most advanced stage of clinical development.

The Leading Players in the Acute Ischemic Stroke Therapeutics Market Include:

AbbVie, Acticor Biotech, Angde Biotech Pharmaceutical, aptaTargets, Athersys|Healios K.K., Bayer, Biogen, Biogen Inc., Bristol-Myers Squibb, Clinuvel Pharmaceuticals, DiaMedica Therapeutics, Genentech, Inc., GNT Pharma, Healios, Janssen Pharmaceutical, JCR Pharmaceuticals, Lumosa Therapeutics, NC Medical Research, NoNO Inc., NuvOx Pharma, Pharmazz, Pharming Group, PT. Prodia Stem Cell Indonesia, Revalesio Corporation, Roche, Shin Poong Pharmaceutical, Shionogi & Co., Ltd., Silver Creek Pharmaceuticals, Supergene, Tasly Pharmaceutical, TrueBinding, Inc, ZZ Biotech, and others.

Acute Ischemic Stroke Emerging and Marketed Drugs Covered in the Report Include:

  • BMS-986177/milvexian: Bristol Myers Squibb Company/Janssen Pharmaceuticals

  • DM199: DiaMedica Therapeutics

  • Glenzocimab: Acticor Biotech

  • Invimestrocel: Healios/Athersys

  • LT3001: Lumosa Therapeutics

  • Nelonemdaz: GNT Pharma

  • Nerinetide: NoNO Inc.

  • SP-8203: Shin Poong Pharmaceutical

  • Tenecteplase: Genentech

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Acute Ischemic Stroke Current Treatment Patterns

4. Acute Ischemic Stroke – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Acute Ischemic Stroke Late Stage Products (Phase-III)

7. Acute Ischemic Stroke Mid-Stage Products (Phase-II)

8. Acute Ischemic Stroke Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Ischemic Stroke Discontinued Products

13. Acute Ischemic Stroke Product Profiles

14. Key Companies in the Acute Ischemic Stroke Market

15. Key Products in the Acute Ischemic Stroke Therapeutics Segment

16. Dormant and Discontinued Products

17. Acute Ischemic Stroke Unmet Needs

18. Acute Ischemic Stroke Future Perspectives

19. Acute Ischemic Stroke Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States